SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (STO:AERO) announces that its airway inflammation monitor, NIOX MINO®, and the NIOX MINO® Test Kit, have received marketing approval for the Australian market. An approval is an important step towards receiving reimbursement for inflammation monitoring with FeNO in asthma management.
